Blueprint Medicines/$BPMC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Blueprint Medicines
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.
Ticker
$BPMC
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
685
ISIN
US09627Y1091
Website
BPMC Metrics
BasicAdvanced
$8.3B
-
-$2.45
0.75
-
Price and volume
Market cap
$8.3B
Beta
0.75
52-week high
$128.45
52-week low
$73.04
Average daily volume
4.8M
Financial strength
Current ratio
2.802
Quick ratio
2.618
Long term debt to equity
171.829
Total debt to equity
208.496
Interest coverage (TTM)
-2.44%
Profitability
EBITDA (TTM)
-158.367
Gross margin (TTM)
96.48%
Net profit margin (TTM)
-27.70%
Operating margin (TTM)
-31.01%
Effective tax rate (TTM)
-1.19%
Revenue per employee (TTM)
$820,000
Management effectiveness
Return on assets (TTM)
-9.75%
Return on equity (TTM)
-47.71%
Valuation
Price to revenue (TTM)
14.473
Price to book
24.18
Price to tangible book (TTM)
24.18
Price to free cash flow (TTM)
-53.912
Free cash flow yield (TTM)
-1.85%
Free cash flow per share (TTM)
-237.70%
Growth
Revenue change (TTM)
99.19%
Earnings per share change (TTM)
-48.18%
3-year revenue growth (CAGR)
36.46%
10-year revenue growth (CAGR)
96.59%
3-year earnings per share growth (CAGR)
-39.46%
10-year earnings per share growth (CAGR)
-23.11%
What the Analysts think about BPMC
Analyst ratings (Buy, Hold, Sell) for Blueprint Medicines stock.
Bulls say / Bears say
Sanofi's acquisition of Blueprint Medicines for over $9 billion underscores confidence in Blueprint's portfolio, particularly Ayvakit, the only approved treatment for advanced and indolent systemic mastocytosis in the U.S. and EU. (reuters.com)
Blueprint Medicines raised its 2025 revenue guidance for Ayvakit to $700-$720 million, reflecting strong global demand and a significant increase in diagnosed systemic mastocytosis patients. (tradingview.com)
The company projects Ayvakit sales to reach $2 billion by 2030, indicating a robust growth trajectory and potential for substantial long-term revenue. (tradingview.com)
Blueprint Medicines reported a Q4 2024 loss of $50 million, or 79 cents per share, missing Wall Street expectations and indicating ongoing financial challenges. (thetelegraph.com)
The company's revenue for Q4 2024 was $146.4 million, falling short of analyst forecasts and suggesting potential difficulties in meeting market expectations. (thetelegraph.com)
Analysts have set a target price of $123.56 for Blueprint Medicines, which is below the current trading price, indicating potential downside risk. (etfdailynews.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
BPMC Financial Performance
Revenues and expenses
BPMC Earnings Performance
Company profitability
BPMC News
AllArticlesVideos
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC
Business Wire·7 days ago
HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Blueprint Medicines Corporation (NASDAQ: BPMC)
GlobeNewsWire·2 weeks ago
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Blueprint Medicines stock?
Blueprint Medicines (BPMC) has a market cap of $8.3B as of June 27, 2025.
What is the P/E ratio for Blueprint Medicines stock?
The price to earnings (P/E) ratio for Blueprint Medicines (BPMC) stock is 0 as of June 27, 2025.
Does Blueprint Medicines stock pay dividends?
No, Blueprint Medicines (BPMC) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Blueprint Medicines dividend payment date?
Blueprint Medicines (BPMC) stock does not pay dividends to its shareholders.
What is the beta indicator for Blueprint Medicines?
Blueprint Medicines (BPMC) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.